PTC slammed after EMA spurns its bid for early OK of DMD drug

John Carroll

Shares of PTC Therapeutics took a hit this morning, dropping about 20% the European Medicines Agency threw its considerable weight against the biotech's application to gain a conditional approval for its Duchenne muscular dystrophy ataluren.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS